5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer

Thirty patients with advanced breast cancer, not pretreated with chemotherapy for advanced disease, received a polychemotherapy regimen containing 5-fluorouracil (500 mg/m 2 iv), epirubicin (50 mg/m 2 iv) and cyclophosphamide (500 mg/m 2 iv) every four weeks. All patients were evaluable for response and for toxicity